News | Heart Valve Technology | July 26, 2018

Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes

Slow progression of disease may mask symptoms until damage cannot be fully repaired

Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes

July 26, 2018 — The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many patients do not undergo surgical intervention until it is too late to completely reverse damage caused by mitral valve disease. The study is posted online in The Annals of Thoracic Surgery.

“This study shows that a significant number of patients are still referred for mitral valve surgery later than they should be,” said James S. Gammie, M.D., from the University of Maryland School of Medicine in Baltimore. “In these cases, the malfunctioning mitral valve has caused significant damage to the heart and/or lungs, and while an operation can be performed, long-term outcomes will be compromised, to some extent.”

Gammie, Vinay Badhwar, M.D., from West Virginia University in Morgantown, W. Va., and colleagues analyzed data from The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD) in order to determine trends related to current mitral valve operations in North America. The ACSD contains more than 6.5 million cardiac surgery procedure records, representing more than 90 percent of all adult cardiac surgery hospitals across the United States and Canada.

The researchers identified 87,214 patients at 1,125 centers who had isolated primary mitral valve operations from July 2011 to September 2016. The average age of patients in this group was 64 years; half were female. During the study period, the number of mitral valve operations performed per year increased by 24 percent, from 14,442 in 2011 to 17,907 in 2016. There was a 44 percent increase in primary mitral operations performed for degenerative disease, the most common form of mitral valve disease in the United States.

“This suggests that the mitral valve disease may have reached a chronic stage prior to referral for operation, which means that heart and lung damage may not be fully reversible,” explained Badhwar. “In these patients, their symptoms may improve after surgery, but their life expectancy may be reduced.”

The mitral valve is the inflow valve between the lungs and the left ventricle, the main pumping chamber of the heart. This valve allows blood to enter the heart from the lungs when the heart muscle is relaxing and also prevents backflow of blood when the heart squeezes. Mitral valve diseases include mitral regurgitation (leaking) and mitral stenosis (narrowing), which may cause fatigue and shortness of breath.

“Once the leakage is severe, heart damage may result, thus mitral valve operation is recommended,” said Badhwar. “The preferred operation is mitral repair, whenever possible. If performed in a timely manner, the patient’s heart function and life expectancy may return to normal.”

In this study, the data showed that the overall repair rate was 65.6 percent (57,244) and the replacement rate was 34.4 percent (29,970). Overall operative mortality was 2 percent (1,762).

“We found that the number of operations performed for mitral valve disease is growing faster than any other category of heart operation and that the results were excellent with low risks of death and complications,” said Gammie.

The researchers also revealed that while the prevalence of mitral valve disease and the number of mitral valve operations performed per year are increasing, overall aortic valve operations were performed 1.6 times more commonly than mitral valve operations during the study period.

“This may suggest important under-referral and under-treatment of mitral valve disease, which may be related to the slower progression of signs and symptoms of mitral compared to aortic disease, as well as potential lack of adherence to guidelines for intervention,” said Gammie. “So although contemporary outcomes are excellent, there remains an important and substantial opportunity to improve results for patients with mitral valve disease by following established guidelines and encouraging earlier referral for operation.”

For more information: www.annalsthoracicsurgery.org

Reference

Gammie J.S., Chikwe J., Badhwar V., et al. "Isolated Mitral Valve Surgery: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis." Annals of Thoracic Surgery, published online July 18, 2018. https://doi.org/10.1016/j.athoracsur.2018.03.086


Related Content

News | Heart Valve Technology

Dec. 26, 2025 — Edwards Lifesciences has announced the company’s SAPIEN M3 mitral valve replacement system, a ...

Home December 24, 2025
Home
News | Heart Valve Technology

Nov. 17, 2025 — Royal Philips has introduced DeviceGuide, an AI-powered device tracking* solution that assists ...

Home November 17, 2025
Home
News | Heart Valve Technology | Cedars-Sinai Medical Center

Oct. 28, 2025 — People who underwent a minimally invasive procedure to have their heart’s aortic valve replaced had ...

Home October 29, 2025
Home
News | Heart Valve Technology

Aug. 28, 2025 — Medtronic plc has announced it received U.S. Food and Drug Administration (FDA) approval for the ...

Home August 29, 2025
Home
News | Heart Valve Technology

Aug. 18, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons ...

Home August 19, 2025
Home
News | Heart Valve Technology

Aug. 4, 2025 — Corcym announced that its Perceval Plus sutureless aortic heart valve was used in a first-ever robotic ...

Home August 05, 2025
Home
News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
Subscribe Now